https://www.selleckchem.com/pr....oducts/Epinephrine-b
Recent advancements in molecular characterisation have identified four principal molecular groups of medulloblastoma WNT, SHH, group 3 and group 4. Each has its characteristic clinical features, signature genetic alterations and distinct DNA methylome profiles. Thus far, CTNNB1 mutations have been considered pathognomonic of WNT-activated medulloblastoma. Furthermore, it has been shown that CTNNB1 mutations dominantly drive the WNT-activated phenotype in medulloblastoma, even in the presence of alterations in
Like
Comment
Share
